AIN457 150 mg

BIOLOGICAL2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Ankylosing SpondylitisModerate to Severe Chronic Plaque-Type Psoriasis

Phase 3

4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

CompletedNCT01640951

Novartis PharmaceuticalsModerate to Severe Chronic Plaque-Type Psoriasis

Start: 2012-09-16End: 2017-05-04Updated: 2018-05-25

Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar)

CompletedNCT03259074

Novartis PharmaceuticalsAnkylosing Spondylitis

Start: 2017-11-30End: 2021-11-29Updated: 2023-08-21

Related Papers

Comparison of the Effects of Secukinumab and Adalimumab Biosimilar on Radiographic Progression in Patients with Ankylosing Spondylitis: Design of a Randomized, Phase IIIb Study (SURPASS).

2020-03-0138 citations

Secukinumab, a fully human anti‐interleukin‐17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years

Journal of the European Academy of Dermatology and Venereology2019-04-2231 citations

Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison

European Journal of Rheumatology2018-10-3014 citations

Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study.

2017-09-0447 citations